Principal Financial Group Inc Affimed N.V. Transaction History

Principal Financial Group Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$0.66 - $1.29 $1,845 - $3,606	-2,796 Reduced 6.01%	43,753 $32,000
Q4 2022 Feb 09, 2023	BUY	$1.1 - $2.45 $28,773 - $64,087	26,158 Added 128.28%	46,549 $57,000
Q3 2022 Nov 09, 2022	SELL	$1.96 - $3.32 $1,807 - $3,061	-922 Reduced 4.33%	20,391 $42,000
Q2 2022 Aug 10, 2022	BUY	$2.27 - $4.86 $138 - $296	61 Added 0.29%	21,313 $59,000
Q1 2022 May 09, 2022	BUY	$3.69 - $5.65 $5,575 - $8,537	1,511 Added 7.65%	21,252 $93,000
Q4 2021 Feb 09, 2022	SELL	$5.37 - $7.07 $24,723 - $32,550	-4,604 Reduced 18.91%	19,741 $109,000
Q3 2021 Nov 09, 2021	BUY	$5.54 - $7.51 $32,043 - $43,437	5,784 Added 31.16%	24,345 $150,000
Q2 2021 Aug 10, 2021	SELL	$7.78 - $11.4 $42,828 - $62,757	-5,505 Reduced 22.87%	18,561 $157,000
Q1 2021 May 10, 2021	BUY	$5.12 - $8.48 $13,009 - $21,547	2,541 Added 11.8%	24,066 $190,000
Q4 2020 Feb 08, 2021	BUY	$3.16 - $7.03 $31,688 - $70,496	10,028 Added 87.22%	21,525 $125,000
Q3 2020 Nov 06, 2020	SELL	$3.26 - $4.73 $2,034 - $2,951	-624 Reduced 5.15%	11,497 $38,000
Q2 2020 Aug 05, 2020	BUY	$1.58 - $4.63 $19,151 - $56,120	12,121 New	12,121 $56,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.